Navigation Links
Novel Drug Delivery Systems Market (NDDS): Formulations (Oral & Injectable) Analysis in Research Report at RnRMarketResearch.com
Date:6/20/2013

Dallas, Texas (PRWEB) June 20, 2013

This comprehensive report on novel drug delivery system focuses mainly on the oral and injectable formulations of pharmaceuticals and specialty companies. This report enumerates the various formulation technologies involved in making value added formulations, pharmaceutical applications and advantages of specific technologies. Wherever possible, marketed drugs using a similar technology have been discussed as proof of validation along with the status of additional pipeline. The discussed proprietary formulation technologies includes Colal, Glide SDI, Arestat, GeoClock, GeoMatrix, FlashTab, Lock Tab, Medusa, Eligen, Oradur, EnteriCare and Saber. This report will be helpful for those pharma companies who are exploring novel opportunities for their growth by in-licensing formulation technology or value added pipeline drugs available/being studied in the market.

The report “Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies” (http://www.rnrmarketresearch.com/innovative-drug-delivery-systems-novel-product-and-formulation-technology-licensing-opportunities-for-generic-pharmaceutical-companies-market-report.html), now available with RnRMarketResearch.com, says there are more than 1400 sustained or controlled release drugs approved all over the world. Revenues within the global generics market reached an estimated value of $265 b in 2012, showing a growth of 9.3% throughout the year. The contribution of generics is approximately 20% of the overall international pharmaceutical market. Utilization of generic in terms of volume is higher in the US and lower in Japan, 89% and 24% respectively.

Novel drug delivery systems (NDDS) offer many more advantages, which include improved therapy by increasing the efficacy and duration of drug activity, increased patient compliance through decreased dosing frequency and convenient routes of administration, and improved targeting for a specific site to reduce unwanted side effects. The challenge for both drug and drug delivery companies is to deliver both existing and emerging drug technologies in a manner that improves the current benefits enjoyed by the patients.

The oral drug delivery market remains the largest slice of the overall drug delivery market, with more than 52% of market share. It is presently valued at $49 billion and is expected to reach over $90 billion by 2016, at a CAGR of 11%. The growth in the oral drug delivery market shall be driven primarily by newer technologies enabling controlled release formulations of oral drugs and oral formulations of injectable only drugs. Global injectable drug delivery market is expected to be worth $29b by 2015. Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=102646.

The generic market with reference to innovative molecule (NCE) has become very competitive as several companies have already filed ANDA’s for potential generic drugs in the near term. The study of the novel drug delivery companies and their formulation technologies will provide the potential value added opportunity in the generic field in terms of patient’s compliance or bioavailability enhancement. It will also provide an enhanced life cycle for drugs under patent coverage (life cycle extension).

The Table of Contents for the report “Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies” cover:
1. Global Generic Business – Present Status and Future Opportunities
2. Therapeutic focus and Trends in Advanced drug Delivery System based on recent deals
3. Patent expiry impact and generic companies strategies –Super generics
4. The relationship between solubility and permeability in formulations
5. Formulation approach for water –insoluble drugs and oral peptide delivery
6. FDA guidelines for 505 (b)(2) applications and advantage of development
7. Types of changes allowed in 505 (b)(2) development and its advantage
8. Regulatory challenges in clinical data requirement in 505(b)(2) development and safety studies
9. Analysis, Application and Advantages of formulations technologies for more than 75 pharma companies with over 100 formulation technologies in oral and injectable formulations discussed
10. Late stage pipeline development for discussed specialty and major Pharma companies
11. The discussed formulations proprietary technologies includes Colal, Glide SDI, Arestat, GeoClock, GeoMatrix, FlashTab, Lock Tab, Medusa, Eligen, Oradur, EnteriCare and Saber.

Explore reports on Prescription Drugs market and related segments @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/prescription-drugs.

About Us:
RnRMarketResearch.com (http://www.rnrmarketresearch.com/) is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. We provide 24/7 online and offline support service to our customers.

Read the full story at http://www.prweb.com/releases/drug-delivery-systems/market-innovations-report/prweb10853186.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation
2. Novel Liver Stem Cell Model Could Speed Up Process for Developing New Drugs
3. Surgeons Complete Clinical Trial on Novel Two-Part Heart Valve
4. New research findings on onset of uterine fibroids provide potential for novel treatments
5. Researchers identify novel approach to create red blood cells, platelets in vitro
6. Discovery of a novel medicine for the treatment of chronic wounds
7. Columbia licenses novel 3-D organ and tumor segmentation software to Varian Medical Systems
8. PolyU Researchers Develop Novel Brain Training Device to Reconnect the Brain and Paralyzed Limb After Stroke
9. Novel study reports marijuana users have better blood sugar control
10. Teen Struggles Through Drug Treatment in Paddy Stewart’s New Novel
11. Expert Panel to Discuss Perspectives on Evaluating Novel Diagnostics for Reimbursement at 2013 Next Generation Dx Summit In Washington, DC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... CARTERSVILLE, Georgia (PRWEB) , ... March 28, 2017 ... ... analyst to its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, ... been a leader in the real estate valuation industry for more than 40 ...
(Date:3/28/2017)... ... March 29, 2017 , ... Dr. Isabella Wentz, PharmD, FASCP, one ... video series titled The Thyroid Secret. Dr. Wentz talked about journey and research recently ... fact that medication IS NOT the only solution to deal with thyroid disease. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... and by physicians, announced today the launch of a free, public-facing tool for ... Cost Analyzer (VCA) was developed to provide comparative information to patients, providers, insurers ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Usually, the impending ... daily wardrobe. However, for those self-conscious about a double chin, this means more anxiety ... ideal solution. , “For most people, a double chin is undesirable,” Dr. Goldman ...
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm , the ... headquarters to a new, more expansive office space in order to accommodate its ... a distressed office building in Wethersfield, Conn. located at 936 Silas Deane Highway ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... REDWOOD CITY, Calif. , March 28, 2017 ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that the European Medicines Agency ... (sufentanil sublingual tablet, 30 mcg) Marketing Authorisation Application ... review of the MAA is underway. The MAA ...
(Date:3/28/2017)... , March 28, 2017  Medeon Biodesign, Inc., ... company, is pleased to announce that the Company ... of Panther Orthopedics, Inc., a San ... fixation solutions for orthopedic extremity applications.  ... expand rapidly, primarily due to procedure volume growth, ...
(Date:3/27/2017)... 2017 Therapix Biosciences Ltd. ... in the development of cannabinoid-based drugs, today announced ... the United States of 2,000,000 ... ordinary shares of the Company, at a price ... granted the underwriters a 45-day over-allotment option to ...
Breaking Medicine Technology: